Post-ASCO Summary: ctDNA as a patient selection and early efficacy marker in drug development

July 27, 2023

Our expert speakers will discuss the latest data from ASCO 2023 and other recent publications and congresses. This will be followed by a panel discussion on the future directions and implications for drug development and clinical trial design in this rapidly evolving space.

Post-ASCO Summary: ctDNA as a patient selection and early efficacy marker in drug development

Using ctDNA to help inform the management of patients with low-risk colorectal cancer (with subtitles)

Using ctDNA to help inform the management of patients with low-risk colorectal cancer

Using ctDNA to help inform the management of patients with locally advanced rectal cancer (with subtitles)

Using ctDNA to help inform the management of patients with locally advanced rectal cancer

The expanding role of ctDNA in colorectal cancer to optimize patient management

The expanding role of ctDNA in colorectal cancer to optimize patient management (with subtitles)

How ctDNA can transform interventional trial design for GI cancers

Seeing the Forest Through the Trees: How tumor informed MRD testing can illuminate the treatment pathway in GI cancer

Seeing the Forest Through the Trees: Using tumor-informed MRD testing to illuminate the treatment pathway in GI cancer

Personalized ctDNA testing to help guide treatment decisions in breast cancer

Webinar: Breast Cancer 2023 Data & Post-SABCS Summary

Panel Discussion: How ctDNA Testing is Informing the Management of Patients With GI Cancer - Direct

Locate and Track: ctDNA Monitoring in NSCLC with Signatera

Keith's Story

ctDNA monitoring to optimize immunotherapy treatment decisions

Detect. Monitor. Optimize: Signatera’s Impact on Breast Cancer Management

Signatera Ordering

Powering Precision: The essential role of ctDNA testing for MRD assessment in GI malignancies - Direct

3988 - Natera - Tampa - Breast Cancer V6e (1)

SABCS 2022 Product Theater Section 1 - The Cycle of ctDNA in Breast Cancer